Jorge L. Posada, MD University of Puerto Rico School of Medicine
Transcript of Jorge L. Posada, MD University of Puerto Rico School of Medicine
![Page 1: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/1.jpg)
Jorge L. Posada, MDUniversity of Puerto Rico School of Medicine
Assistant Professor of Internal MedicineNephrology Fellow
4/17/08
![Page 2: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/2.jpg)
OutlineBasics of transplantationBenefits of transplantationImmunosuppressive medicationsCommon post-transplant problems
![Page 3: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/3.jpg)
Basics of TransplantationKidney transplantation is the most effective
therapy for end-stage renal disease.The transplanted organ can come from either
a live donor or deceased donor.Most deceased donor organs come from
brain dead donors.Non-standard criteria donors:
Expanded criteria donors (ECD).Donation after cardiac death (DCD).
![Page 4: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/4.jpg)
Anatomy of Renal Transplantation
![Page 5: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/5.jpg)
Recipient SelectionVery few contraindications.General medical condition.Cardiovascular screening.Age-appropriate routine cancer screening (pap
smear, mammography, colonoscopy, PSA).Infection (HIV, Hepatitis, TB).Presence of preformed antibody (PRA).
Pregnancy, prior transplant, blood transfusionPsychosocial evaluation, including compliance.
![Page 6: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/6.jpg)
Benefits of TransplantationLife expectancyCardiovascular benefitsQuality of lifeSocioeconomic benefits
![Page 7: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/7.jpg)
Life Expectancy
Ojo, J Am Soc Neph, 2001;12:589
![Page 8: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/8.jpg)
Cardiovascular Benefits
Foley, Am J Kidney Dis, 1998;32(S1):8Slide courtesy of Dr. Robert Gaston
![Page 9: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/9.jpg)
Quality of LifeNumerous studies have detailed improved
quality of life.Life satisfaction, physical and emotional well-
being and ability to return to work higher in transplant recipients.
Uremic complications more fully reversed.Fertility returns.
![Page 10: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/10.jpg)
Socioeconomic BenefitsIncreased rates of return to work.Cost to society:
Annual cost of hemodialysis: $60,000-$80,000First year after transplantation: >$100,000Thereafter: $10,000 per year.
Mean cumulative costs of dialysis and transplantation are equal for first 3-4 years, then lower for transplantation.
![Page 11: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/11.jpg)
Immunosuppressive Medications
Slide courtesy of Dr. Meier-Kriesche
![Page 12: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/12.jpg)
Three-Signal Model
Halloran, N Eng J Med, 2004;351:3715
![Page 13: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/13.jpg)
Immunosuppressive MedicationsInduction:
CorticosteroidsAnti-thymocyte globulin (ATG)IL-2 receptor antagonists
Maintenance:CorticosteroidsCalcineurin inhibitors (CNIs)mTOR inhibitorsAntimetabolites
![Page 14: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/14.jpg)
Immunosuppressive MedicationsTreatment of Rejection:
CorticosteroidsAnti-thymocyte globulinIntravenous Immunoglobulin (IVIG)RituximabPlasmapheresis
![Page 15: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/15.jpg)
CorticosteroidsUsed for induction, maintenance and
treatment of rejection.Mechanism of action:
Inhibit function of dendritic cells.Inhibit translocation to nucleus of NF-κB.Suppress production of IL-1, IL-2, IL-3, IL-6,
TNF-α, and γ-IFN.Adverse effects numerous and well-known.
![Page 16: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/16.jpg)
Halloran, N Eng J Med, 2004;351:3715
![Page 17: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/17.jpg)
CorticosteroidsComponent of >80% of transplant protocols.Given IV at high doses (250-500 mg/day) for
induction or treatment of rejection.Tapered to maintenance dose of 5-10 mg/day
in early post-transplant phase.Should NOT be tapered off: increased risk of
rejection and graft loss!Steroid free regimen: overall some benefits
but graft survival likely worse.
![Page 18: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/18.jpg)
Anti-thymocyte Globulin (Thymoglobulin®)Used for induction and treatment of rejection.Prepared by immunization of rabbits with
human lymphoid tissue.Causes depletion of peripheral blood
lymphocytes.Administered generally via central line for 3-10
days.Premedication required: acetaminophen,
corticosteroids and antihistamine.
![Page 19: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/19.jpg)
Anti-thymocyte Globulin: Adverse EffectsInfusion-related reactions: chills, fevers,
arthralgias.Lymphopenia.Thrombocytopenia.Prolonged immunosuppression: increased
risk of opportunistic infections (PCP, CMV, fungal).
Possibly increased risk of BK virus nephropathy.
![Page 20: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/20.jpg)
IL-2 Receptor BlockersBasiliximab (Simulect®) and Daclizumab
(Xenapax®).Block CD25 (IL-2 receptor) on activated T
cells.Used for induction only.Almost no side effects, but also much less
potent.
![Page 21: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/21.jpg)
Halloran, N Eng J Med, 2004;351:3715
![Page 22: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/22.jpg)
Calcineurin InhibitorsUsed for maintenance immunosuppression.Two agents in clinical practice:
Cyclosporine (Sandimmune®, Gengraf®, Neoral®, generic; CysA)
Tacrolimus (Prograf®, generic; FK506).Generics NOT clinically therapeutically
equivalent.At present are key to maintenance
immunosuppression and a component of the majority of transplant protocols.
![Page 23: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/23.jpg)
Calcineurin Inhibitors: Mechanism of ActionCsA: Cyclosporine
FK506: Tacrolimus
FKBP: FK Binding Protein
CpN: Cyclophilin
NF-AT: Nuclear Factor of Activated T-cells (c- cytosolic component; n- nuclear component).
Stepkowski, Expert Rev Mol Med, 2000;2(4):1
![Page 24: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/24.jpg)
Halloran, N Eng J Med, 2004;351:3715
![Page 25: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/25.jpg)
Calcineurin Inhibitors: Dosing and Monitoring
Both medications are generally dosed twice per day, 12 hrs apart.
Trough levels monitored: check approximately 12 hrs after last dose.
In some cases C2 levels might be checked 2 hrs after administration.
Cyclosporine is 35-40% bioavailable, tacrolimus approximately 25%.
Oral to IV conversion 3-4:1. Both are metabolized by cytochrome P450 3A4
& 3A5.
![Page 26: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/26.jpg)
Calcineurin Inhibitors: Interactions
Halloran, from Johnson (ed.), Comprehensive Clinical Nephrology, Mosby Elsevier, 2003.
![Page 27: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/27.jpg)
Calcineurin Inhibitors: InteractionsDrugs to use with caution:
NSAIDs—avoid.Amphotericin B & Aminoglycosides– worsened
nephrotoxicity.ACEi & ARBs– use with caution.Statins– avoid lovastatin, start others at lowest
possible dose.
![Page 28: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/28.jpg)
Calcineurin Inhibitors: P-Glycoprotein P-Glycoprotein (P-gp, also known as MDR1)
is an ABC-transporter found among other places, in the intestine.
It is thought to have evolved as a defense mechanism against harmful substances.
It acts as an efflux pump for many substances including drugs (CNIs, colchicine, some cancer chemotherapeutic agents, digoxin, corticosteroids, antiretrovirals).
Decreased P-gp expression, such as in diarrhea, leads to elevated drug levels.
![Page 29: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/29.jpg)
Calcineurin Inhibitors: Adverse EffectsNephrotoxicity:
Functional decrease in blood flow from afferent arteriolar vasoconstriction.
Thrombotic microangiopathy (rare).Chronic interstitial fibrosis.Hyperkalemia, hypomagnesemia and type IV
renal tubular acidosis.Cyclosporine thought to be more nephrotoxic.
![Page 30: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/30.jpg)
Calcineurin Inhibitors: Adverse EffectsCyclosporine Tacrolimus
Hypertension ++ +
Pancreatic islet toxicity
+ ++
Neurotoxicity + ++
Hirsutism + -
Hair loss - +
Gum hypertrophy + -
GI side effects - +
Gastric motility - +
Dyslipidemia + -
Hyperuricemia ++ +
↑K+/↓Mg2+ + +Adapted from Danovitch, Handbook of Kidney Transplantation, Lippincott Williams & Wilkins,
2005
![Page 31: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/31.jpg)
mTOR InhibitorsTarget site is the mammalian target of
rapamycin (mTOR), a key regulatory kinase in cell division.
Sirolimus (Rapamune®) only available mTOR inhibitor in the US.
Administered once daily, 24-hour trough levels monitored.
Also metabolized by P450 3A system, with interactions similar to the CNIs.
![Page 32: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/32.jpg)
Sirolimus: Mechanism of ActionSRL: Sirolimus
FKBP: FK Binding Protein
mTOR: Mammalian target of rapamycin
Cdk: cyclin-dependent kinase
Stepkowski, Expert Rev Mol Med, 2000;2(4):1
![Page 33: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/33.jpg)
Halloran, N Eng J Med, 2004;351:3715
![Page 34: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/34.jpg)
Sirolimus: Adverse EffectsNephrotoxicity:
Delays recovery from ATN.Potentiates cyclosporine nephrotoxicity.Induces proteinuria.Tubulotoxic.
Impairment of wound healing.Dyslipidemia (increased LDL and TGs).Pneumonitis.Cytopenias and anemia.
![Page 35: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/35.jpg)
AntimetabolitesAzathioprine (Imuran®, generic) is a purine
analogue that is incorporated into RNA and inhibits cell replication.
A mainstay of transplantation for 30 years, it has largely been replaced by the below drugs.
Mycophenolate mofetil (Cellcept®) and enteric-coated mycophenolate sodium (Myfortic®) are prodrugs of mycophenolic acid (MPA), an inhibitor of inosine monophosphate dehydrogenase (IMPDH).
![Page 36: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/36.jpg)
Mechanism of Action: MPA Prodrugs
Stepkowski, Expert Rev Mol Med, 2000;2(4):1
![Page 37: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/37.jpg)
Halloran, N Eng J Med, 2004;351:3715
![Page 38: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/38.jpg)
Antimetabolites: Adverse EffectsAzathioprine:
Bone marrow suppression.Hepatitis.Azathioprine is inactivated by xanthine
oxidase, therefore should not be used in combination with allopurinol.
MPA prodrugs:GI toxicity: diarrhea, nausea, esophagitis.Leukopenia and anemia.Not different between formulations.
![Page 39: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/39.jpg)
Antimetabolites: InteractionsAzathioprine:
AllopurinolOther marrow suppressive drugs
MPA prodrugs:CyclosporineAntacidsCholestyramineFerrous sulfateOK to use with allopurinol
![Page 40: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/40.jpg)
Intravenous Immune GlobulinUsed primarily for treatment of antibody-
mediated rejection.Mechanism of action:
Reduction of alloantibodies through suppression of antibody formation.
Increased catabolism of circulating antibodies.Adverse effects:
Infusion-related reactions (myalgias, headaches).
Severe headache & aseptic meningitis.Autoimmine hemolytic anemia.Sucrose-based IVIG can cause ARF.
![Page 41: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/41.jpg)
Rituximab Used in the treatment of antibody-mediated
rejection. Monoclonal antibody directed at CD20 antigen
on B lymphocytes. Causes rapid and sustained depletion of B
lymphocytes. Does not have direct activity against plasma
cells and memory B cells, which do not express CD20.
Adverse events: infusion reactions, and increased susceptibility to infection.
![Page 42: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/42.jpg)
Other Agents OKT3
Used for induction and treatment of rejection, now largely replaced by anti-thymocyte globulin.
Monoclonal antibody against CD3 Severe infusion reactions (pulmonary edema &
capillary leak syndrome). Alemtuzumab (Campath-1H®)
Monoclonal anti-CD52 antibody Toxicities include bone marrow suppression and
severe infections Leflunomide (Arava®)
Dihyroorotate dehydrogenase (DHODH) inhibitor. Used in certain clinical settings as an adjunct
immunosuppressive.
![Page 43: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/43.jpg)
Common Complications of Transplantation
Early complications Surgical complications Delayed or slow graft function Lymphocele
Acute rejection Acute cellular rejection Antibody-mediated rejection
Infectious complications Cytomegalovirus BK virus Others
Malignancy Chronic allograft dysfunction
![Page 44: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/44.jpg)
Surgical Complications Graft thrombosis:
Caused by thrombosis of donor renal artery or vein. Usually happens in first week. Diagnosed by ultrasound with doppler studies. Almost always requires explant of kidney.
Urine leak: Elevated creatinine. May or may not have abdominal pain. Diagnose with nuclear medicine scans (DTPA or
MAG3). Surgical repair and/or relief of obstruction.
![Page 45: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/45.jpg)
Delayed Graft FunctionNeed for dialysis in the first week after
transplantation.Causes:
ATN from prolonged cold ischemia.Acute rejection.Recurrent disease.
Usually requires biopsy for diagnosis and management.
![Page 46: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/46.jpg)
LymphoceleCollection of lymph caused by leakage from
iliac lymphatics.Presents several weeks post-operatively.Symptoms:
Compression of kidney, ureter, bladder: obstructive uropathy and ARF.
Compression of iliac vessels: unilateral lower extremity edema and DVT.
Abdominal mass.Treatment is surgical.
![Page 47: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/47.jpg)
Acute RejectionMay present with ARF or proteinuria.Diagnosis made by biopsy.Pathology is reported according to Banff
classification.Acute cellular rejection: treat with steroids or
ATG based on severityAntibody-mediated rejection: may require
steroids, ATG, rituximab, IVIG or plasmapheresis based on severity and setting.
![Page 48: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/48.jpg)
Banff ‘05 Classification
Solez, Am J Transplant, 2007;7:518
![Page 49: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/49.jpg)
Cytomegalovirus Most common viral infection after
transplantation. Various degrees of severity:
Asymptomatic CMV viremia CMV syndrome (viremia plus constitutional
symptoms) CMV end-organ or invasive disease (hepatitis,
gastritis, colitis, pneumonitis) Risk factors:
Use of antibody induction Donor seropositive, recipient seronegative status
![Page 50: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/50.jpg)
CytomegalovirusClinical presentation:
Asymptomatic (detected on screening)NeutropeniaMalaise & constitutional symptomsGI CMV: gastritis, colitis, esophagitisClinical hepatitis, pneumonitis
Prophylaxis:All patients at risk (D+/R+, D-/R+ or D+/R-)
receive valganciclovir prophylaxis for 4.5-6 months.
“Preemptive” strategy with CMV PCR monitoring.
![Page 51: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/51.jpg)
CytomegalovirusCMV PCR assays have largely replaced pp65
antigenemia for diagnosis.Low-level viremia can be treated with full-
dose oral valganciclovir (900 mg bid, dose-adjusted for renal function).
High-grade viremia or invasive disease requires 2-4 week course of IV ganciclovir, which may be followed by oral valganciclovir.
Ganciclovir-resistant cases might require foscarnet or cidofovir.
![Page 52: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/52.jpg)
BK Virus Disease BK virus is a member of the polyomavirus
family. An increasingly important cause of allograft
failure. Latent in genitourinary tract and reactivated by
immunosuppression. Usually presents in first year after
transplantation. Asymptomatic viruria or viremia BK-associated interstitial nephritis BK virus nephropathy
![Page 53: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/53.jpg)
BK Virus DiseaseScreening is by BK viral PCR in blood or urine.Presence of BK virus titers >10,000 is
suggestive but not diagnostic of BK nephropathy.
Diagnosis can only be established by biopsy.Options for therapy:
Judiciously reduce immunosuppressionUse of leflunomideIVIG (especially in simultaneous rejection & BK
nephropathy).
![Page 54: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/54.jpg)
BK Virus Monitoring Algorithm
Randhawa, Brennan, Am J Transplant, 2006;6:2000
![Page 55: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/55.jpg)
Other InfectionsTransplant patients have increased
susceptibility to all other common infections.Opportunistic infections can also be seen:
Pneumocystis jirovicii pneumoniaCandida infectionToxoplasmosisNocardiosisCryptococcus infections
![Page 56: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/56.jpg)
Malignancy Recipient of organ transplants are at higher
risk of developing malignancy. May be related to impaired immune
surveillance as a result of immunosuppression. Skin cancer most common: sun protection
mandatory. Routine cancer screening. Specific malignancies:
Kaposi sarcoma Post-transplant lymphoproliferative disorder
(PTLD)
![Page 57: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/57.jpg)
Chronic Allograft DysfunctionPersistent rise in serum creatinine and
worsening GFR over weeks to months is termed chronic allograft dysfunction.
Histological counterpart is chronic allograft nephropathy (CAN).
Characterized by nonspecific interstitial fibrosis and tubular atrophy.
Usually irreversible and will lead to allograft failure and need for dialysis or retransplantation.
![Page 58: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/58.jpg)
Chronic Allograft Dysfunction: Why Do Grafts Fail?Chronic low-grade immune injuryLong-standing hypertensionRecurrent disease (diabetic nephropathy or
glomerulonephritis)Repeated episodes of acute rejectionDonor diseaseCalcineurin inhibitor nephrotoxicity
![Page 59: Jorge L. Posada, MD University of Puerto Rico School of Medicine](https://reader033.fdocuments.us/reader033/viewer/2022052901/556af983d8b42a2a4f8b4a31/html5/thumbnails/59.jpg)
THANK YOU.ANY QUESTIONS?
My appreciation to Dr. Shezad Rehman for providing slides.